MBX Biosciences, Inc. Common Stock
MBXMBX Biosciences, Inc. (MBX) is a biotechnology company focused on developing treatments for metabolic and cardio-metabolic diseases. The company leverages its proprietary platforms to discover and develop novel therapeutics aimed at improving patient outcomes in conditions such as non-alcoholic steatohepatitis (NASH) and related metabolic disorders.
Company News
MBX Biosciences announced positive one-year data from its open-label extension study of canvuparatide, a once-weekly PTH replacement therapy for chronic hypoparathyroidism. The drug maintained a 57% responder rate at one year with a 90% retention rate, demonstrated sustained benefits in calcium homeostasis, kidney function, and bone metabolism, a...
AstraZeneca announced that its investigational drug eneboparatide (AZP-3601) met the primary endpoint in the Phase 3 CALYPSO trial for chronic hypoparathyroidism. The therapy demonstrated that 31.1% of patients achieved normal calcium levels and independence from vitamin D and calcium supplements at week 24, compared to 5.9% in the placebo group....
MBX Biosciences announced preliminary Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug showing 7% mean weight loss at 8 weeks with good tolerability and potential for once-monthly dosing. The company also nominated MBX 5765, a novel four-agonist candidate for obesity, and achieved proof of concept for imapextide in post-bariatric hypogly...
MBX Biosciences announced the appointment of Karen Basbaum as Chief Business Officer and issued her an equity inducement award of 130,000 non-qualified stock options with an exercise price of $32.29 per share. The options vest over four years with a 10-year term, approved by the board as a material inducement for her employment.
MPM BioImpact sold its entire 1.3 million share stake in MBX Biosciences, worth $14.8 million, during Q3 2025, just before the company's pivotal clinical trials and potential key milestones in 2026.
